ProCE Banner Activity

DNA Repair Deficiencies and the Promise of PARP Inhibition in Prostate Cancer: Clinical Implications

Multimedia
In this on-demand Webcast of a CCO symposium at AUA 2018 for the practicing urologist, CCO’s expert faculty explore PARP inhibitor therapy in prostate cancer, including a review of the latest data on DNA repair deficiencies, insights into practical challenges associated with genetic testing for DNA repair defects, and a review of available clinical data on PARP inhibitors and how these agents may affect management strategies for patients in the near future.

Released: June 22, 2018

Expiration: June 21, 2019

No longer available for credit.

Share

Faculty

William B. Isaacs

William B. Isaacs, PhD

Professor
Department of Urology
Johns Hopkins School of Medicine
Baltimore, Maryland

Todd M. Morgan

Todd M. Morgan, MD

Associate Professor
Department of Urology
University of Michigan
Ann Arbor, Michigan

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

AstraZeneca

Learning Objectives

  • Describe the rationale and process for assessing germline and somatic DNA repair pathway alterations in prostate cancer
  • Examine the mechanism of PARP inhibition to achieve “synthetic lethality” in prostate cancer with deficient BRCA1/2
  • Evaluate the available clinical evidence for the use of PARP inhibitors to treat metastatic CRPC harboring BRCA1/2 or ATM mutations
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor monotherapy or in combination with other agents or therapies in prostate cancer

Faculty Disclosure

Primary Author

William B. Isaacs, PhD

Professor
Department of Urology
Johns Hopkins School of Medicine
Baltimore, Maryland

William B. Isaacs, PhD, has no real or apparent conflicts of interest to report.

Todd M. Morgan, MD

Associate Professor
Department of Urology
University of Michigan
Ann Arbor, Michigan

Todd M. Morgan, MD, has disclosed that he has received consulting fees from Myriad Genetics and funds for research support for GenomeDx, MDxHealth, and Myriad Genetics.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.